TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Safety of gemcitabine administration
Endpoint domain: Adverse events/effects
Primary endpoint: Variation of NIPE index (∆NIPE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pre-procedure wellness score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Intra- and post-procedural vomiting, aspiration, and intubation checklist
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Glasgow Coma Scale (GCS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: PK of Brexanolone: Maximum Observed Plasma Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 90-day postoperative cardiovascular complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Complete re-epithelialization of the wound of donor area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: change in severity and symptoms of constipation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Strategy success
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Blood pressure systolic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood pressure diastolic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood pressure mean
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Polysomnography (PSG)-Apnea Hypopnea Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Polysomnography (PSG)-Oxygen Desaturation Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Polysomnography (PSG)-Minimum Oxygen Saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Polysomnography (PSG)-Oxygen Saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of abnormal vital signs
Endpoint domain: Adverse events/effects
Primary endpoint: Gastrointestinal functional recovery (first bowel movement)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Gastrointestinal functional recovery (first flatus passage)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Gastrointestinal functional recovery (first stool passage)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Presence of subjective arm lymphedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Presence of subjective trunk/ breast lymphedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Presence of objective arm lymphedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Presence of objective trunk/ breast lymphedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Eczema Area and Severity Index (EASI 90)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Worst Pruritus Numerical Rating Scale (WP-NRS 0/1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in dual blind read CT ICOERD score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of IT administration adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of adverse events attributed to the investigational product
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical gingival inflammation at 3 month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Standardized Mini Mental Test (SMMT) score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Brachial-arterial flow-mediated vasodilation (baFMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline Best-Corrected Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of eligible participants approached that consent
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of participants who consent that are randomized
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Average enrolment rate of participants per centre per month
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Total intraoperative fluid volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Midnight Plasma ACTH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Turnover of proteins in humans
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efgartigimod serum concentrations for Clearance (CL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efgartigimod serum concentrations for Volume Distribution (Vd)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total G immunoglobulins (IgG) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-acetylcholine receptors antibodies (AChR-Ab)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life-child Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Serum prealbumin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in extracellular inorganic pyrophosphate (PPi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Pyridoxal 5'-phosphate (PLP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Difference in pulmonary function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Difference in diffusion capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: MRI Bold Beta Weights
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physician Global Improvement Assessment (PGIA)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Students' educational level
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: syndecan-1 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in dystrophin protein level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in relationship satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in constructive communication
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Cell membrane expression rate of ANXA2 on circulating monocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of patients achieving and maintaining major molecular response (MMR) at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensory peripheral innervation (IENF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Autonomic peripheral innervation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline on Psychological distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline in well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Peak cardiac output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Development of new caries lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intervertebral distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Skin - epidural distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of Participants who Achieve Endoscopic Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Benton Judgement of Line Orientation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Brief Visuospatial memory test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: NIH Toolbox Picture Sequence Memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Beery Developmental Test of Visual Motor Integration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Beery Developmental Test of Visual Perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Wechsler Intelligence Scale for Children -V Block Design
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Overall Safety of StroMel
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Clinically Significant Laboratory Test Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Clinically Significant Vital Signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical measurement of pocket depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical measurement of clinical attachment level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: metagenomic analysis of the relative abundance of bacterial from subgingival plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change on the WHO clinical progression scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Imaging Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Device-related Adverse Event Detection
Endpoint domain: Adverse events/effects
Primary endpoint: Total volume of resuscitation fluids delivered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients With Analyzable Data
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Test My Brain Neurocognitive Assessment performance: Global Cognition Z Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in Leuven Postprandial Distress Scale (LPDS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in Anxiety level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Average pain score after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of decline in Forced Vital Capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Difference in redness of Ultraviolet B induced erythema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Weekly number of connections to the application
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Response rate to the weekly questionnaires
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of participants with adverse events of special interest
Endpoint domain: Adverse events/effects
Primary endpoint: Uncorrected Distance Visual Acuity (UCDVA) of 20/40 or better
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with VTE events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Fugl-Meyer Assessment for Upper Extremity (FMA-UE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Modified Ashworth scale of muscle spasticity (MAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Medical Research Council scale (MRC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percent work time missed due to ADHD
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percent overall work impairment due to ADHD
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Percent overall classroom impairment due to ADHD
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Fold change in % γH2AX positive cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Effects of intravenous immunoglobulin therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Satisfaction of feasibility criteria
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Safety Evaluation of AZD0486
Endpoint domain: Adverse events/effects
Primary endpoint: Result of the Horne and Ostberg questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: percentage of patients with at least one episode of atrial arrythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Unplanned Hospital Applications
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of BGB-43395
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Parosmia Olfactory Dysfunction Outcomes Rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical performance of direct restorations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in BSID-III Gross Motor Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants alive post-Chemo Radiation Therapy
Endpoint domain: Mortality/survival
Primary endpoint: Mean number of lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-CHIPS antibody levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Activation-induced cytidine deaminase (AID) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of intraoperative hypertension and hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ricker sedation-agitation score after surgery
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Toxicity side effect
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with TEAEs leading to dose modification or discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of Grade ≥2 AE or SAE related to study bNAbs
Endpoint domain: Adverse events/effects
Primary endpoint: Time from ART discontinuation to HIV-1 RNA ≥1,000 copies/mL for 4 consecutive weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of participants with a minimum four-fold rise in post-vaccination HPV-16 and HPV-18 neutralizing antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pharmacokinetics of Darunavir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of live birth children with major congenital malformations
Endpoint domain: Mortality/survival
Primary endpoint: Percent of participants who took up genetic testing after not meeting NCCN guidelines for genetic testing
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean overall patient satisfaction with decision about genetic testing
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall comprehension as assessed by BCGCKQ
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Total amount of exchange plasma (prescribed vs achieved exchange volume)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in elbow pain (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Interferon-gamma Spot Forming Units (IFN-γ SFUs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Set of biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total and Unbound Penicillin-V Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite endpoint of mortality or dialysis dependency at 90 days
Endpoint domain: Mortality/survival
Primary endpoint: Neurometabolite profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pumped milk volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DHCA level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Experience a Dose Limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Experience a Treatment-emergent Adverse Event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Experience a Treatment-related Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: C-peptide increase from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: stone free rate post-operative
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline hematocrit after 1 day postoperative
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: time of operation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: ZEB-1 Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Type III Interferon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: PD-L1 Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: RV16 Viral Titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants With Dose-Limiting Toxicities (DLTs) During the DLT Evaluation Period
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Adverse Events (AEs) and Treatment-Related AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Objective Response according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as assessed by Investigator
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: VAS score (average pain intensity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depression, Stress, Anxiety Scale (DASS21)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: EORTC QLQ - C30 Quality of Life Scale/ LC-13 Lung Module
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Scale of Adjustment to Chronic Diseases
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Aortic Pulse Wave Velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in Gastrointestinal Angiodysplasia (GIAD) Foci
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Vascular Reactivity Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Knee Related Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Sports and Recreational Function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Validation of ClinRO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The recommended phase 2 dose (RP2D)
Endpoint domain: Resource use
Primary endpoint: Pre-transfusion platelet count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Total platelet transfusion dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from baseline in the Neuropsychiatric Inventory - Nursing Home Version (NPI-NH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-Stigma Questionnaire - Post-Intervention
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Self-Stigma Questionnaire - Follow-Up
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Help Seeking Intentions (3 items of the ATSPPH) - Post-Intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Help Seeking Intentions (3 items of the ATSPPH) - Follow-Up
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sway Velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sway area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perimeter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of TruTag, via System Usability Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acceptability of TruTag, via Qualitative Interviews
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Complete response (CR) or partial response (PR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes